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Complete evaluation of chromatographic behavior and establish-
ment of optimal experimental conditions for determination of
torasemide and its four impurities are determined by experimental
design. Fractional factorial and 3n full factorial design were
employed for efficient and rapid optimization of liquid chromatog-
raphy–ultraviolet and liquid chromatography–mass spectrometry
(LC–MS) methods.
Separation is achieved on a Zorbax SB C18 analytical column
(250 x 4.6 mm, 5 mm) with mobile phase consisting of acetonitrile
and 10 mM ammonium formate (pH 2.5 with formic acid) in gradi-
ent mode. The flow rate is 1 mL min21, the temperature of the
column is 258C and UV detection is performed at 290 nm. The effi-
ciency of ionization in electrospray ionization is higher than in
atmospheric pressure chemical ionization mode; therefore, it is
further used for analysis of torasemide and its impurities. Both
methods meet all validation criteria. The calibration curves show
high linearity with the coefficients of correlation (r) greater than
0.9982. The obtained recovery values (95.78–104.92%) and relative
standard deviation values (0.12–5.56%) indicate good accuracy and
precision. Lower limit of detection (LOD) and limit of quantitation
(LOQ) values are obtained with the LC–MS method, indicating
higher sensitivity of the proposed method.
Introduction
Torasemide (Figure 1A) is a loop diuretic. Its chemical
structure, 1-isopropyl-3-(4-m-toluidinopyridine-3-sulphonyl)
urea, is not related to other loop diuretics, such as furosemide,
although their mechanisms of actions are similar (1, 2).
Torasemide acts in the ascending limb of the Henle loop by
inhibiting tubular reapsorption of sodium and chloride and
interacting with the sodium/chloride/potassium/ co-transport
system (3, 4). It has been considered suitable for a broad
spectrum of clinical settings, including heart failure, hepatic
cirrhosis, hypertension and chronic renal failure (5).
Impurities present in the dosage forms might lead to
problems associated with toxicity, bioavailability or different
pharmaceutical products’ performance. According to
International Conference on Harmonization (ICH) guidelines
on impurities in new drug products, identiﬁcation and quanti-
tation is necessary for all impurities above 0.1% level (6, 7).
Therefore, the paramount of modern pharmaceutical analysis
is determination of the active ingredients and their impurities
to assure a high quality of products, without changes in
chemical, pharmacological and toxicological properties.
Impurities of torasemide that could occur in the drug product
are 4-(3-methylphenylamino)-3-pyridinesulfonamide (R2,
Figure 1B), N-(ethylaminocarbonyl)-4-(3-methylphenylamino)-
3-pyridinesulfonamide (R3, Figure 1C), N-(butylaminocarbonyl)-
4-(3-methylphenylamino)-3-pyridinesulfonamide (R6, Figure 1D)
and 3,4-dihydro-4-(3-methylphenyl)-2H-pyrido[4,3-e]-1,2,4-
thiadiazine-1,1-dioxide (R4, Figure 1E). Impurities R3 and R6
can be formed during synthesis by a parallel reaction between
4-(3-methylphenylamino)-3-pyridinesulfonamide and ethyliso-
cyanate or butylisocyanate, and are synthetic impurities.
Impurity R2 is both a potential degradation product and syn-
thetic impurity, because during synthesis of torasemide it can
be disintegrated to impurity R4 (8). The control speciﬁcation
for all listed impurities is up to a maximum of 0.3%.
During a literature survey, several methods for the analysis of
torasemide and its metabolites in human plasma and urine have
been found. These include high-performance liquid chromatog-
raphy (HPLC) with ultraviolet (UV) (9, 10) or electrochemical
detection (11), gas chromatographic–mass spectrometry(GC–
MS) (12) and capillary zone electrophoresis with an experi-
mental design approach (13). Also, liquid chromatography–
mass spectrometry (LC–MS) (14–17) and capillary electro-
phoresis (18) methods were found for the determination of
torasemide in a mixture of diuretics in urine.
However, to our knowledge, there is no work about the sim-
ultaneous determination of torasemide and its four impurities
in pharmaceutical dosage forms. Therefore, the aim of this
work was evaluation of the chromatographic behavior and de-
velopment of sensitive, reliable LC–MS and LC–UV methods
for determination of torasemide and its impurities in pharma-
ceutical dosage form. The complete chromatographic behavior
and optimal chromatographic conditions were evaluated with
the assistance of experimental design. In this way, maximum
information was obtained with a limited number of experi-
ments. Because impurities are usually present in small quan-
tities, it was decided to develop the LC–MS method. This
technique couples high resolution chromatographic separation
with sensitive and speciﬁc mass spectrometric detection,
which is clearly advantageous, particularly because many com-
pounds with similar or identical retention characteristics have
quite different mass spectra and can therefore be differen-
tiated. (19). In this way, the MS detection could reveal the pres-
ence of potentially unknown impurities in dosage form. The
presented method is planned to be used in further forced deg-
radation studies. Two ionization modes, electrospray ionization
(ESI) and atmospheric pressure chemical ionization (APCI) for
LC–MS analysis of all ﬁve compounds were evaluated. HPLC
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with UV detection is a widely used analytical technique in
quality control of pharmaceuticals. For those reasons, simultan-
eous LC–MS and LC–UV methods have been developed.
Both analytical methods were successfully validated in
accordance with ICH guidelines (20). The selectivity, limits of
detection and quantiﬁcation, linearity, accuracy and precision
(repeatability) were determined and obtained results were
compared. Subsequently, the applicability of the proposed
methods on the tablet dosage form has been demonstrated.
Experimental
Chemicals and reagents
Standards of torasemide, impurities R2, R3, R4, R6 and Diuver
tablets (containing 10 mg of torasemide) were obtained from
Pliva (Zagreb, Croatia). All reagents were of analytical grade.
Acetonitrile (Merck, Germany), ammonium formate (Fluka,
Germany) and formic acid (Merck, Germany) were used to
prepare the mobile phase. Water for chromatography was deio-
nized using an Easy pure RF (Barnstead) puriﬁcation system.
The mobile phase was prepared daily, degassed and vacuum
ﬁltered before use through a Millipore 0.45 mm (47 mm diam-
eter) nylon membrane ﬁlter (Millipore, Milford, MA). Millex
syringe driven ﬁlter units of 0.45 mm (Millipore, Milford, MA)
were used to ﬁlter the samples.
Equipment
The LC coupled mass spectrometer detector system Agilent
1100 series (Agilent Technologies, Germany) consisted of binary
pump, degasser, thermostated autosampler, thermostated
column compartment, diode-array detector and a single quadru-
pole mass analyzer (G1946D). Data collection and processing
were performed using Agilent Chemstation software (Agilent
Technologies, Germany). Design-ExpertSoftware version 7.0,
Excel 2003 and Statistica 8 were used for statistical analysis.
Chromatographic conditions
The chromatographic separation was performed on a Zorbax SB
C18 analytical column (250 x 4.6 mm, 5 mm, Agilent) with column
temperature set at 258C. The mobile phase was an aqueous solu-
tion of 10 mM ammonium formate, adjusted to pH 2.5 with
formic acid (mobile phase A) and acetonitrile (mobile phase B),
with gradient elution: 0 min, B 30%; 11.2 min, B 60%; 11.3 min, B
30 %, hold for 10 minutes. The ﬂow rate was 1 mL min21 and
the injection volume was 30 mL for LC–UV analysis and 10 mL
for LC–MS analysis. Detection was performed at 290 nm.
Mass spectrometric conditions
An ESI technique was used. All analytes were analyzed in posi-
tive ionization mode. Optimization of LC–MS conditions was
carried out using ﬂow injection analysis (FIA) of the analytes
(10 mL of 10 mg mL21 standard solutions for all substances).
The optimized parameters of the interface were: drying gas
(N2) ﬂow rate, 12.0 L min
21; nebulizer gas pressure, 60 psig;
temperature, 3508C; capillary voltage, 3000 V; gain, 2. To quan-
tify torasemide and its impurities, selective ion monitoring
(SIM) of protonated molecular ions [M þ H] þ at m/z: 349 (tor-
asemide), 264 (impurity R2), 276 (impurity R4), 335 (impurity
R3) and 363 (impurity R6) was used.
Standard solutions
Stock solution of torasemide was prepared by dissolving the
standard substance in the acetonitrile–water (50:50, v/v) to
Figure 1. (A) Structure of torasemide; structures of impurities: (B) R2, (C) R3, (D) R6, (E) R4.
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obtain a ﬁnal concentration of 1 mg mL21. Stock solutions of
each impurity were prepared by dissolving the standard sub-
stances of R2, R3, R4 and R6 in the acetonitrile–water (50:50,
v/v) to obtain a ﬁnal concentration of 0.1 mg mL21.
For linearity testing, seven standard solutions of torasemide
and its impurities were prepared diluting stock solutions with
acetonitrile–10 mM ammonium formate, pH 2.5 (50:50, v/v).
For the LC–UV analysis, the concentration ranges for torase-
mide and its impurities were 70–130 and 0.1–10 mg mL21,
respectively. For the LC–MS analysis, the concentration ranges
were 0.7–1.3 mg mL21 for torasemide and 0.01–1.0 mg mL21
for impurities.
The investigation of accuracy and precision of the method was
evaluated at three concentrations of torasemide and its impur-
ities. For the LC–UV analysis, the concentration levels for torase-
mide and its impurities were 70, 100 and 130 mg mL21 and 0.1,
1.0 and 10 mg mL21, respectively. For the LC–MS analysis, the
concentration levels were 0.7, 1.0 and 1.3 mg mL21 for torase-
mide and 0.01, 0.1 and 1.0 mg mL21 for impurities. The solutions
for investigation of accuracy of the method were prepared
adding known amount of the analyte into the placebo mixture.
The limit of detection (LOD) and limit of quantitation (LOQ)
were determined with solutions obtained by diluting the stock
solution of each compound with acetonitrile–10 mM ammo-
nium formate, pH 2.5 (50:50, v/v).
All solutions were protected from light due to light sensitiv-
ity of the investigated substances. Under the stated experimen-
tal conditions, during development and validation procedures,
stability related problems were not noticed with the standard
and sample solutions.
Preparation of sample solutions
An amount of powdered tablets that contained 10 mg of torase-
mide was transferred to a 50 mL volumetric ﬂask and dissolved
in approximately 35 mL of acetonitrile–water (50:50, v/v)
with the assistance of an ultrasonic bath for 15 min. The solu-
tion was then diluted to volume with the same solvent and
ﬁltered through a 0.45 mm ﬁlter. For the LC–UV analysis, the
ﬁltered solution was diluted with acetonitrile–10 mM ammo-
nium formate, pH 2.5 (50:50, v/v) to produce the expected
torasemide concentration of 0.1 mg mL21. For the LC–MS ana-
lysis, solution with torasemide concentration of 0.1 mg mL21
was further diluted with acetonitrile–10 mM ammonium
formate, pH 2.5 (50:50, v/v) to obtain torasemide concentra-
tions of 0.01 and 0.001 mg mL21 for related substances and
assay tests, respectively. All solutions were freshly prepared
before analysis and kept protected from light.
Results and Discussion
Optimization of chromatographic conditions
In separation science, development of a method involves deter-
mination of the optimal experimental conditions that enable
sufﬁcient resolution of the relevant peaks and furnish adequate
and robust assay results in an acceptable analysis time (21). The
HPLC is primarily based on partition separation mechanism of
the analytes between the mobile and stationary phases, which
mostly depends on the properties of the analytes, pH and
composition of the mobile phase and type of stationary phase
(22). Therefore, based on the nature of the investigated sub-
stances, the stationary phase was chosen and further optimal
chromatographic conditions were determined with the assist-
ance of fractional factorial 24–1 and 3n full factorial design.
Torasemide and its four impurities have very similar physical-
chemical properties. The logP values are 1.97, 1.31, 1.55, 2.52
and 1.70 for torasemide, R2, R3, R6 and R4, respectively. The
C18 packing columns were shown to be the most suitable
according to the lipophilic nature of the compounds. Initially,
four columns were examined (Zorbax Extend C18, Xterra RP18,
Chromolith RP18 and Zorbax SB C18) and it was decided to
continue the investigation on Zorbax SB C18. This decision was
based on the properties of this column, which is packed with
speciﬁc, spherical microparticles, allowing high efﬁciency of
separation, compatibility with the high-sensitivity detectors
and typical volatile mobile phase additives used for LC–MS.
Use of this column enabled tight, symmetrical peaks with good
separation of all analyzed compounds.
Among organic modiﬁers used in reversed phase (RP)–
HPLC, it was decided to use acetonitrile based on better peak
symmetries and shorter analysis run time. The addition of
buffer was inevitable, and buffers suitable for LC–MS analysis
were examined (ammonium formate, ammonium acetate and
triﬂuoroacetic acid). Concentrations of these buffers were
varied in the range from 5–10 mM. The best combination of
ionization efﬁciency and chromatographic peak shape was
found with the 10 mM ammonium formate; higher concentra-
tions of the buffer were not investigated because they are not
recommended when an MS detector is used.
All compounds are ampholyts with two pKa values. The ﬁrst
pKa is the same for all substances and arose from basic proper-
ties of the compounds (pKa1torasemide, R2, R3, R4, R6 ¼ 4.20).
The second pKa arose from acidic properties and differs
among compounds (pKa2torasemide, R3, R6 ¼ 5.92, pKa2R2 ¼
9.62, pKa2R4 ¼ 9.46). Therefore, it was expected that the pH
Table I
Investigated Variables and their Levels Studied in the FFD 24-1 and 32 Full Factorial Designs
Variables Investigated levels
–1 0 þ1
(x1) Acetonitrile (%) 20 / 60
(x2) pH value of the water phase 2.0 2.5 3.0
(x3) Temperature of the column 15 25 35
(x4) Strength of the buffer (mM) 0 / 10
Table II
Plan of the Experiments for the FFD 24-1 Design for Four Variables and Corresponding Retention
Factors for Torasemide and its Impurities
Exp. no. Variables Retention factors
x1 x2 x3 x4 R2 R4 R3 Torasemide R6
1 21 21 21 21 2.70 3.18 9.43 18.11 36.64
2 þ1 21 21 þ1 0.18 0.25 0.25 0.37 0.66
3 21 þ1 21 þ1 3.56 4.71 7.21 14.46 34.89
4 þ1 þ1 21 21 0.21 0.21 0.21 0.21 0.44
5 21 21 þ1 þ1 2.34 2.66 8.57 16.68 30.19
6 þ1 21 þ1 21 0.09 0.13 0.17 0.23 0.44
7 21 þ1 þ1 21 1.91 2.70 5.00 9.43 25.89
8 þ1 þ1 þ1 þ1 0.19 0.39 0.10 0.19 0.35
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of the water phase would have a signiﬁcant inﬂuence on the
retention behavior of the investigated ampholytes. This
assumption was conﬁrmed during preliminary experiments and
it was decided to vary the pH of the water phase from 2–3. A
pH above 3 was not investigated because molecules of torase-
mide and its impurities exist in molecular and ionic shapes.
The inﬂuence of the temperature of the column was investi-
gated in the range from 15–358C. These are commonly used
temperatures in HPLC methods.
The fractional factorial design (FFD) was used to detect all
variables that signiﬁcantly inﬂuenced the chromatographic
procedure. The aim of the screening phase is to decrease the
number of experiments by determination of variables that
have statistically signiﬁcant inﬂuence on the chromatographic
system (23). The number of experiments in FFD is given as
2k2p þ C, where k is the number of variables, C is the number
of replicates at the central point and p is a whole number that
indicates how fractionated the experimental design is. When p
is zero, the experimental design is full (24). The 24–1 FFD
resulting from eight experiments was conducted and the reten-
tion factors were the observed responses (25). The investigated
variables and their domains are presented in Table I. High and
Figure 2. Representative Pareto charts of standardized effects (absolute value) obtained from the FFD show the influence of studied variables on the retention factors of R2,
R3, R4, torasemide and R6.
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low levels of each variable were deﬁned during preliminary
experiments and are denoted as þ1 and 21. The observed
response during FFD was the retention factor of all analyzed
substances. The experimental plan of FFD and obtained reten-
tion factors are reported in Table II. All experiments were
performed randomly and without repetition, except four
experiments at the central point that enabled estimation of the
statistical importance of the variables.
According to the obtained retention factors, the estimated
effects and standardized effects were calculated. Critical t-value
for a ¼ 0.05 and 3 degrees of freedom (DF) was 3.182 for all
substances. All factors whose absolute values of the standar-
dized effects are above critical t-value are statistically signiﬁcant
and those below this value are statistically insigniﬁcant. Pareto
charts, of which the length of the bars is proportional to the
absolute value of the standardized effects, are presented in
Figure 2. The dashed line represents critical t-value and the im-
portance of the presented variables can easily be observed.
In further work, statistically signiﬁcant variables, percentage
of acetonitrile, pH of the water phase and temperature of the
column were thoroughly studied by employing optimization
design. Similar structures and therefore similar chromatograph-
ic behavior of all ﬁve compounds caused difﬁculties in deﬁn-
ition of the range of organic modiﬁer. No range of acetonitrile
could simultaneously satisfy acceptable separation and appro-
priate analysis run time. Therefore, it was necessary to establish
a gradient elution. The developed gradient mode was reported
in detail in a previous section. Two remaining variables were
evaluated employing three-level full-factorial design. The previ-
ously mentioned design contains all possible combinations
between the n variables on 3 levels, requiring N ¼ 3n experi-
ments (21). The experimental domain and plan of experiment
are presented in Tables I and III, respectively. Controllable
factors were held constant at deﬁned levels (10 mM ammonium
formate buffer according to better peak symmetries and gradi-
ent elution) and all experiments were performed randomly.
Two responses were examined: retention factors for torase-
mide and its impurities and resolution between critical pair
(impurities R2 and R4). The obtained responses for every
experiment are presented in Table III. According to the results
of experiments, the following response surface models were
computed:
y ¼ 0:94þ 0:23x1  0:087x2  0:0025x1x2 þ 0:13x21
þ 0:0067x22 ;
where y represents the retention factor of impurity R2,
y ¼ 1:16þ 0:26x1  0:085x2 þ 0:017x1x2 þ 0:057x21
þ 0:0017x22 ;
where y represents the retention factor of impurity R4,
y ¼ 1:53þ 0:12x1  0:092x2 þ 0:01x1x2 þ 0:18x21 þ 0:0017x22 ;
where y represents the retention factor of impurity R3,
y ¼ 2:09 0:04x1  0:093x2 þ 0:03x1x2  0:003x21  0:003x22 ;
where y represents the retention factor of torasemide,
y ¼ 2:96 0:08x1  0:13x2 þ 0:037x1x2  0:005x21 ;
where y represents the retention factor of impurity R6,
y ¼ 3:41þ 0:521 þ0:22 þ0:321 x2  1:0821 0:03522;
where y represents the resolution between impurities R2
and R4.
The x1 represents the pH of the mobile phase and x2 repre-
sents the column temperature.
The 3D response surface graphs were obtained when system
response was plotted against two quantitative variables (26).
The 3D graphs for each of the evaluated responses are pre-
sented in Figure 3. Impurities R2 and R4 have the most similar
chromatographic behavior; therefore, problems due to separ-
ation were expected. Similar chromatographic behavior was
observed for torasemide and impurity R6, but regarding reten-
tion parameters, they are not close enough to disable the
separation. To choose optimal chromatographic conditions, the
resolution between the critical pair of impurities R2 and R4
was also evaluated. As concluded from the 3D graph, optimal
separation could be achieved with a temperature of 258C and
pH of the water phase of 2.5. With these chromatographic
conditions, satisfactory separation and acceptable analysis time
were achieved.
Summarizing all the facts, it was clear that optimal chromato-
graphic conditions included a mobile phase consisting of
acetonitrile–10 mM ammonium formate buffer with pH
adjusted to 2.5 in gradient mode. Column temperature was set
at 258C, ﬂow rate was 1 mL min21 and detection was per-
formed at 290 nm. Under these conditions, retention factors
(k) and peak symmetry (As) for all compounds, in addition to
resolution (Rs) between peaks, were satisﬁed and fulﬁlled all
requirements of system suitability testing (27). The values of
system suitability parameters are presented in Table IV.
Optimization of MS conditions
Two ionization modes, ESI and APCI, for LC–MS analysis of
torasemide and its impurities were evaluated.
According to the literature for torasemide (16, 28–30), both
positive and negative modes for ESI and APCI could be applied.
Because the production of positive ions is favored at acidic pH
Table III
Plan of Experiments in 3n Full Factorial Designs for Torasemide, R2, R3, R4 and R6
Exp. no. Variables Retention factors Resolution
x2 x3 R2 R4 R3 Torasemide R6 R2/R4
1 21 21 0.93 1.06 1.69 2.24 3.20 1.87
2 21 þ1 0.76 0.86 1.48 2.00 2.88 1.71
3 21 0 0.84 0.95 1.58 2.12 3.04 1.79
4 þ1 21 1.39 1.54 1.91 2.10 2.95 2.22
5 þ1 þ1 1.21 1.41 1.74 1.98 2.78 3.36
6 þ1 0 1.29 1.48 1.82 2.04 2.86 2.88
7 0 21 1.03 1.25 1.61 2.18 3.09 3.28
8 0 þ1 0.86 1.07 1.44 1.98 2.82 3.49
9* 0 0 0.94 1.16 1.53 2.09 2.96 3.49
*Four replicates at the center point
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(optimal chromatographic conditions), the positive mode was
chosen. Positive ion mode, with a mobile phase consisting of
ammonium formate–formic acid buffer and acetonitrile,
involves the creation of [M þ H]þ ions and the possible pres-
ence of solvent adduct ions such as [M þ NH4]þ, [M þ H þ
ACN]þ and [M þ NH4 þ ACN]þ (15). In this study, the solvent
Figure 3. 3D graphs of the response surface for retention parameters of R2, R4, R3, torasemide and R6, and resolution factor for impurities R2 and R4 as a function of column
temperature and pH.
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adduct ions, having very low intensities, were also detected.
FIA was performed to determine the presence of diagnostic
ions for each compound and to optimize MS parameters: vapor-
izer temperature, corrona current, capillary voltage, nebulizer
pressure, drying gas ﬂow and drying gas temperature.
The vaporizer temperature was varied from 250 to 4508C in
positive APCI. The maximum intensity of signals of protonated
molecular ions was achieved at 4508C.
The corona current was varied from 2 to 10 mA and the
optimal values for all compounds were found at 8 mA. The ca-
pillary voltage was varied between 2000 and 4000 V. A slight
improvement of sensitivity was observed at 3000 V.
The drying gas ﬂow rate was varied from 3 to 9 L min21 and
the optimum ﬂow rate was found at 6 L min21. The nebulizer
pressure was tested between 30 and 60 psig, with no signiﬁ-
cant inﬂuence on the response (set at 60 psig). Conversely, an
increase of gas temperature positively affected on the response
of compounds, and gas temperature at 3508C was set as
optimal (varied between 200 and 3508C).
For ESI, the capillary voltage, nebulizer pressure and drying
gas temperature were varied in the same range as for APCI and
the following optimal values were found: capillary voltage,
3000 V; nebulizer pressure, 60 psig; drying gas temperature
3508C and drying gas ﬂow was set at 12.0 L min21 (high
ﬂow rate).
APCI and ESI in positive ion mode provided the formation of
protonated molecular ions [M þ H] þ at m/z: 349 (torasemide);
264 (impurity R2); 276 (impurity R4); 335 (impurity R3); 363
(impurity R6) as well as the characteristic product (fragment)
ions of the studied analytes. Fragmentation of torasemide and
its impurities R4, R3 and R6, leads to formation of fragment
ions amongst which the fragment ion with m/z ratio corre-
sponding to m/z ratio of protonated molecular ion of impurity
R2 was also observed. Moreover, torasemide and impurities R3
and R6 gave the same fragment ion at m/z 290, due to the
chemical structure similarity of compounds. To establish a reli-
able method for the simultaneous determination of torasemide
and its impurities, it was necessary to achieve an optimal chro-
matographic separation. That goal is accomplished and is pre-
sented in a previous section.
Generally, more fragments could be found under the optimal
conditions in the APCI mode, useful for identiﬁcation purposes
(in ESI mode, impurity R4 showed poor fragmentation with
only one fragment ion found at m/z 183). On the other hand,
the efﬁciency of ionization in ESI was higher than APCI and
therefore more appropriate for quantitative applications.
Considering the advantages and disadvantages of both APCI
and ESI methods, ESI in positive mode was used for further ana-
lysis of torasemide and its impurities (SIM mode for quantiﬁca-
tion purposes and mass spectral data as well as retention time
of target compounds for peak identiﬁcation).
Table V presents the protonated molecular ion and fragment
ions of torasemide and impurities R2, R4, R3 and R6 in ESI
mode, with optimal fragmentor voltage. Mass spectra in ESI
mode are presented in Figure 4.
Method validation
After the optimization procedure, the validation was performed
according to the validation protocols that comply with the
international guidelines on method validation (20). The object-
ive of validation of an analytical procedure is to demonstrate
that it is suitable for its intended purpose. The selectivity, lin-
earity, accuracy, precision (repeatability), LOD and LOQ were
determined for both LC–UV and LC–MS methods.
The selectivity was investigated by observing potential inter-
ferences between torasemide and its impurities with tablet
excipients. The placebo mixture showed no peaks at the reten-
tion times of the compounds analyzed. Therefore, both
methods showed good selectivity. Representative UV chroma-
tograms of placebo mixture (Figure 5A) and working standard
mixture (Figure 5B) are shown in Figure 5.
The linearity of an analytical procedure is its ability to obtain
test results that are directly proportional to the concentration
(amount) of analyte in the sample. The linearity was examined
in the concentration range of 70–130 mg mL21 for torasemide
and 0.1–10 mg mL21 for impurities R2, R3, R4 and R6 by apply-
ing LC–UV. The concentrations range of torasemide was 0.7–
1.3 mg mL21 and 0.01–1.0 mg mL21 for its impurities in LC–
MS. The speciﬁed ranges for the assay (70–130 % of torase-
mide expected concentration) and determinations of impur-
ities (0.1–10 % of torasemide declared content in the sample)
were derived considering ICH guidelines (20, 7). Each of these
solutions was injected three times. Linear relationships of peak
areas against concentrations were obtained by using the least
squares method. Data from regression analysis of each compo-
nent are presented in Table VI. The high linearity over the
entire concentration range was demonstrated with the coefﬁ-
cients of correlation (r) greater than 0.9982. Hence, it can be
concluded that the linearity is satisﬁed for both LC–UV and
LC–MS methods.
The closeness of the measured value to the true value is its
accuracy, which was calculated as recovery value of the known
Table IV
System Suitability Data
Compound Retention time (tr) Retention factor (k) Symmetry (As) Resolution (Rs)
R2 4.937 0.94 0.98
R4 5.448 1.16 0.98 3.49a
R3 6.142 1.53 0.98 4.84b
Torasemide 7.373 2.09 0.74 6.28c




d torasemide and R6
Table V













R2 263 264 183/168 120 240
R4 275 276 183 160 200
R3 334 335 290/264 70 160
Torasemide 348 349 290/264 70 170
R6 362 363 290/264 100 180
aFragmentor voltage for protonated molecular ion
bFragmentor voltage for fragment ions
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Figure 4. ESI–MS spectra of: (A) torasemide, (B) R2, (C) R4, (D) R3, (E) R6.
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Figure 5. Representative UV chromatograms of: (A) placebo mixture, (B) working standard mixture, (C) sample solution of torasemide tablets.
Table VI
Regression Analysis Data, LOD and LOQ Values for LC–UV and LC–MS Methods
Compound LC–UV LC–MS
y ¼ ax þ b* r LOD mg mL21 LOQ mg mL21 y ¼ ax þ b* r LOD mg mL21 LOQ mg mL21
R2 90.281x þ 4.577 0.9997 0.020 0.060 4E þ 07x þ 432007 0.9997 0.0003 0.0009
R4 84.479x þ 2.117 0.9999 0.025 0.075 4E þ 07x þ 138278 0.9999 0.0002 0.0006
R3 65.636x þ 4.582 0.9998 0.030 0.090 3E þ 07x þ 733744 0.9982 0.0004 0.0012
Torasemide 66.785x-145.6 0.9989 0.035 0.100 9E þ 06x þ 547684 0.9990 0.0002 0.0006
R6 59.995x þ 5.552 0.9998 0.030 0.090 3E þ 07x þ 789633 0.9983 0.0002 0.0006
* n ¼ 7
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added amount of analyte spiked into placebo mixture. On the
other side, the precision (repeatability) was assessed as relative
standard deviation (RSD) of a series of measurements. Accuracy
and precision studies were performed at three different con-
centrations with three replicates covering the speciﬁed range.
For the LC–UV analysis, the concentration levels were 70, 100
and 130 mg mL21 for torasemide and 0.1, 1.0 and 10 mg mL21
for impurities. For the LC–MS analysis, the concentration levels
were 0.7, 1.0 and 1.3 mg mL21 for torasemide and 0.01, 0.1 and
1.0 mg mL21 for impurities. The results from examination of
accuracy and precision are presented in Table VII. The
obtained recovery values indicated good accuracy of both
methods. Taking the RSD for each concentration into consider-
ation, both LC–UV and LC–MS methods showed satisfactory
precision.
The minimum level at which the analyte can be reliably
detected (LOD) and quantiﬁed (LOQ) were determined experi-
mentally for both methods. LOD and LOQ were deﬁned as the
amounts for which the signal-to-noise ratios were 3:1 and 10:1,
respectively (20). These data are presented in Table VI.
All obtained validation parameters fulﬁlled the require-
ments according to ICH regulations. Comparing the methods,
LC–UV shows better precision, whereas the LC–MS method
is 50–100-fold more sensitive. After validation, the applicabil-
ity of the method for determination of torasemide and im-
purities R2, R3, R4 and R6 was examined by analyzing
commercially available Diuver tablets. The torasemide
content was 96.3% determined by LC–UV and 0.15% for im-
purity R2. The impurities R3, R4 and R6 were not detected
in LC–UV analysis. In LC–MS analysis, the content of torase-
mide was 96.8% and the content of impurity R2 was 0.16%.
The impurities R3 and R6 were not detected, whereas im-
purity R4 was found below LOQ in LC–MS analysis. The
results obtained by quantitative analysis met acceptance cri-
teria. The low RSD value (less than 2%) for all determinations
(n ¼ 3) conﬁrm the suitability of both methods, LC–UV and
LC–MS, for the routine determination of torasemide and its
impurities in dosage form. Chromatogram of sample solution
of torasemide tablets obtained using LC–UV detection is dis-
played in Figure 5C.
Conclusion
LC–UV and LC–MS methods for simultaneous determination
of torasemide and its impurities have been developed and vali-
dated. The experimental design is shown to be useful tool for
evaluation of chromatographic behavior and optimal chromato-
graphic conditions of the investigated substances. For both
methods, the calibration curves showed high linearity over a
wide concentration range and all requirements for method ac-
curacy and precision are fulﬁlled. Compared to LC–UV analysis,
LC–MS analysis added speciﬁcity that improved sensitivity
(lower LOD and LOQ values were obtained) and increased con-
ﬁdence in the results of qualitative analysis of analytes. The
proposed LC–MS method could be very valuable in further in-
vestigation during forced degradation studies. Considering val-
idation parameters, both methods are sensitive, speciﬁc and
reproducible enough to be applied in the quality control of tor-
asemide and its impurities in active pharmaceutical ingredients
and pharmaceutical dosage forms.
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